Literature DB >> 31255194

Extent of Surgery for Low-Risk Differentiated Thyroid Cancer.

Alexandria D McDow1, Susan C Pitt2.   

Abstract

Although the incidence of thyroid cancer is increasing, survival remains unchanged. Due to concern for overtreatment, surgical management of thyroid cancer has evolved. Papillary thyroid microcarcinoma measuring 1 cm or smaller are considered very low risk and can be managed with either thyroid lobectomy or active surveillance. Total thyroidectomy is no longer recommended for these cancers unless there is evidence of metastasis, local invasion, or aggressive disease. Recommendations for low-risk differentiated thyroid cancer measuring 1 cm to 4 cm remain controversial. This article explores the controversies over the extent of surgery for patients with very low-risk and low-risk differentiated thyroid cancer.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Active surveillance; Differentiated thyroid cancer; Extent of resection; Low-risk thyroid cancer; Surgery; Thyroid cancer; Thyroid lobectomy; Thyroidectomy

Mesh:

Year:  2019        PMID: 31255194     DOI: 10.1016/j.suc.2019.04.003

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  10 in total

1.  The Influence of Emotions on Treatment Decisions About Low-Risk Thyroid Cancer: A Qualitative Study.

Authors:  Susan C Pitt; Megan C Saucke; Benjamin R Roman; Stewart C Alexander; Corrine I Voils
Journal:  Thyroid       Date:  2021-11-26       Impact factor: 6.568

2.  The role of surgery in small differentiated thyroid cancer.

Authors:  Firas Baidoun; Omar Abdel-Rahman
Journal:  Endocrine       Date:  2022-06-03       Impact factor: 3.925

3.  Factors associated with physicians' recommendations for managing low-risk papillary thyroid cancer.

Authors:  Alexandria D McDow; Benjamin R Roman; Megan C Saucke; Catherine B Jensen; Nick Zaborek; Jamia Linn Jennings; Louise Davies; Juan P Brito; Susan C Pitt
Journal:  Am J Surg       Date:  2020-11-12       Impact factor: 3.125

4.  Which is preferred for initial treatment of papillary thyroid cancer, total thyroidectomy or lobotomy?

Authors:  Zhen Wu; Lin Han; Wenlei Li; Wei Wang; Liqaing Chen; Yumin Yao; Yongkun Wang
Journal:  Cancer Med       Date:  2021-01-29       Impact factor: 4.452

5.  Analysis of the Rehabilitation Efficacy and Nutritional Status of Patients After Endoscopic Radical Thyroidectomy by Fast Track Surgery Based on Nutritional Support.

Authors:  Fang Qu; Hongxia Bu; Liu Yang; Hui Liu; Chaoying Xie
Journal:  Front Surg       Date:  2022-05-02

6.  Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery.

Authors:  Soon Min Choi; Dong Gyu Kim; Ji-Eun Lee; Joon Ho; Jin Kyong Kim; Cho Rok Lee; Sang-Wook Kang; Jandee Lee; Jong Ju Jeong; Woong Youn Chung; Kee-Hyun Nam
Journal:  Gland Surg       Date:  2022-09

7.  Endoscopic-assisted lateral neck dissection and open lateral neck dissection in the treatment of lateral neck lymph node metastasis in papillary thyroid carcinoma: A comparison of therapeutic effect.

Authors:  Tao Ma; Shuai Zhang; Dongmei Huang; Gang Zhang; Boyi Chen; Ning Zhang
Journal:  Pak J Med Sci       Date:  2022 Sep-Oct       Impact factor: 2.340

8.  Predictive features of central lymph node metastasis in papillary thyroid microcarcinoma: Roles of active surveillance in over-treatment.

Authors:  Bo Han; Sen Hao; Jixiang Wu; Jugao Fang; Zhengxue Han
Journal:  Front Med (Lausanne)       Date:  2022-09-26

9.  With High-Risk Factors, Total Thyroidectomy is Preferred for Thyroid Cancer.

Authors:  Lin Han; Wenlei Li; Yingxue Li; Wenjuan Wen; Yumin Yao; Yongkun Wang
Journal:  Cancer Manag Res       Date:  2020-05-20       Impact factor: 3.989

10.  Patients' Reaction to Diagnosis with Thyroid Cancer or an Indeterminate Thyroid Nodule.

Authors:  Susan C Pitt; Megan C Saucke; Elizabeth M Wendt; David F Schneider; Jason Orne; Cameron L Macdonald; Nadine P Connor; Rebecca S Sippel
Journal:  Thyroid       Date:  2020-11-04       Impact factor: 6.568

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.